Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM - PACE-CME

Reductions in LVOT gradients NYHA class and NTproBNP with cardiac myosin inhibitor in HCM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term efficacy and safety of radiofrequency renal denervation
Long-term efficacy and safety of radiofrequency renal denervation
ACC.22
Long-term efficacy and safety of radiofrequency renal denervation
- Felix Mahfoud, MD
EHR-based intervention improves quality care for patients with HF
EHR-based intervention improves quality care for patients with HF
ACC.22
EHR-based intervention improves quality care for patients with HF
- Tariq Ahmad, MD
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
ACC.22
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
- Brian Bergmark, MD
PCSK9i reduces plaque burden in coronary arteries
PCSK9i reduces plaque burden in coronary arteries
ACC.22
PCSK9i reduces plaque burden in coronary arteries
- Prof. Lorenz Räber, MD, PhD